eyewire

Orbis Marks 20 Years in Macau with First Flying Eye Hospital Simulation Training Project

Key Takeaways Orbis' first Flying Eye Hospital simulation project in Macau will train 70 ophthalmologists and nurses from ...
eyewire

Nidek Launches RSD-1 Duo, AFC-1, and EyeLink Platform Ahead of ESCRS 2026

Nidek has launched the RSD-1 Duo OCT/Fundus Camera, AFC-1 Non-mydriatic Auto Fundus Camera,and EyeLink Eye Care Data Management Platform The RSD-1 Duo combines expanded OCT imaging and fundus ...
eyewire

Drug Farm Releases Phase 1b Data Showing Systemic Improvements with DF-003 in ROSAH Syndrome

Key Takeaways Interim phase 1b findings showed ophthalmic responses in 3 of 5 evaluable Chinese participants, with individual ...
eyewire

X-Cel and Essilor Launch Lunara Overnight Orthokeratology Lens

X-Cel Specialty Contacts and Essilor Custom Contacts have launched Lunara, an FDA PMA-approved overnight orthokeratology lens made from 180 Dk Optimum Infinite material Lunara uses familiar tangential ...
eyewire

Antibiotic Injection Associated with Lower Endophthalmitis Risk After Cataract Surgery, Meta-Analysis Finds

A Bayesian meta-analysis of 54 studies and more than 6.8 million cataract surgeries found antibiotic injection was associated with an approximately 79% reduction in the odds of postoperative ...
eyewire

Sightview Launches Updated Ophthalmology EHR and Practice Management Platform

Sightview has launched an updated EHR and practice management platform designed specifically for ophthalmology practices The platform introduces a redesigned interface, streamlined workflows, an ...
eyewire

Harrow Reports Lower Patient Discomfort with Iheezo Versus Proparacaine After Intravitreal Injections

Patients reported approximately 58% less overall discomfort in Iheezo-treated eyes compared with fellow eyes receiving proparacaine, with statistically significant differences at all 4 assessments The ...
eyewire

Lupin and Tenpoint Announce Strategic Partnership to Commercialize Yuvezzi in Europe

Lupin and Tenpoint Therapeutics have entered into a partnership, providing VISUfarma exclusive rights to commercialize Yuvezzi (carbachol and brimonidine tartrate ophthalmic solution) 2.75%/0.1% in ...
eyewire

FDA Expands TearCare's Indication to Include Improvement of Meibomian Gland Function

The FDA updated TearCare's indication to include improving meibomian gland function in adults with dry eye disease due to meibomian gland dysfunction (MGD); it is the first and only treatment with ...
eyewire

B+L Advances Two Ophthalmic Pipeline Therapies in DED and Ocular Surface Pain

First Patient Enrolled in Phase 3 Trial of Ocugen's Gene Therapy for GA ...
eyewire

Annexon Adds Month 24 Primary Endpoint to Phase 3 ARCHER II Trial of Vonaprument for GA

Annexon added a Month 24 dual primary endpoint to ARCHER II while retaining the phase 3 trial’s Month 15 primary endpoint An independent DMC is expected to assess the Month 15 primary endpoint in the ...
eyewire

First Patient Receives Investigational Regenerative Cell Therapy for Non-Syndromic Retinitis Pigmentosa

The first patient has undergone subretinal implantation of DSP-3077 in a phase 1/2a study for non-syndromic retinitis pigmentosa The 12-participant study will primarily evaluate the safety and ...